Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions

Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-toControl Type 2 Diabetes" With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes Results demonstrate a hypercortisolism prevalence rate of 24 percent in this patient popul ...